thalidomide has been researched along with Skin Diseases in 97 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Skin Diseases: Diseases involving the DERMIS or EPIDERMIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide use in cutaneous sarcoidosis is based on data from small case series or case reports." | 9.19 | A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. ( Chevrant-Breton, J; Chosidow, O; Cosnes, A; D'Incan, M; Desseaux, K; Droitcourt, C; Dupin, N; Dupuy, A; Joly, P; Juillard, C; Lacour, JP; Lebrun-Vignes, B; Misery, L; Porcher, R; Revuz, J; Rybojad, M; Sassolas, B; Tazi, A; Valeyre, D, 2014) |
| "To evaluate feasibility and efficacy of prolonged treatment with thalidomide for cutaneous sarcoidosis associated to pulmonary involvement in patients with resistance or contraindications to steroids." | 9.16 | Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. ( Antonelli, A; Barachini, P; Calabrese, R; Carpi, A; Cei, G; Cristofani, R; Fazzi, P; Manni, E; Piazza, S; Siciliano, G, 2012) |
| "We sought to assess the efficacy and tolerance of thalidomide for cutaneous sarcoidosis." | 9.11 | Treatment of cutaneous sarcoidosis with thalidomide. ( Cordoliani, F; Dupuy, A; Lebbé, C; Morel, P; Nguyen, YT; Rybojad, M; Vignon-Pennamen, MD, 2004) |
| "Thalidomide was an effective form of treatment for chronic cutaneous sarcoidosis." | 9.10 | Thalidomide for chronic sarcoidosis. ( Baughman, RP; Judson, MA; Lower, EE; Moller, DR; Teirstein, AS, 2002) |
| "We evaluated the antifibrotic effects of pomalidomide in preventive as well as therapeutic treatment regimes using bleomycin-induced dermal fibrosis as a model of early, inflammatory stages of fibrosis and the tight-skin mouse model as a model of later stages of fibrosis with endogenous activation of fibroblasts." | 7.78 | Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. ( Beyer, C; Cedzik, D; Dees, C; Distler, A; Distler, JH; Distler, O; Palumbo-Zerr, K; Schafer, PH; Schett, G; Shankar, SL; Tomcik, M; Weingärtner, S; Zerr, P, 2012) |
| "Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM)." | 7.71 | The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. ( Grover, JK; Raina, V; Uppal, G, 2002) |
| "Data from ten patients with sarcoidosis treated with thalidomide between January 1998 and March 1999 were collected from delivery authorizations and analyzed." | 7.71 | [Sarcoidosis: thalidomide treatment in ten patients]. ( Bressieux, JM; Cosnes, A; Estines, O; Revuz, J; Roujeau, JC; Wolkenstein, P, 2001) |
| "A patient with sarcoidosis was treated with thalidomide for disfiguring and painful steroid unresponsive sarcoidal granulomas of the skin." | 7.70 | Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. ( Koblenzer, PS; Lee, JB, 1998) |
| " Because administration of low doses of thalidomide has been successful in treating other inflammatory diseases, it was used in a patient with systemic sarcoidosis who was unresponsive to corticosteroids and in a patient with pulmonary sarcoidosis, in whom Kaposi's sarcoma developed after a course of corticosteroid therapy." | 7.69 | Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. ( Bonaccorsi, P; Calvieri, S; Carlesimo, M; Giustini, S; Rossi, A, 1995) |
| "Treatment with thalidomide stopped the progression of the disease in two cases." | 5.91 | Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report. ( Abdollahimajd, F; Diab, R; Kaddah, A; Rakhshan, A; Shahidi Dadras, M, 2023) |
| "Thalidomide use in cutaneous sarcoidosis is based on data from small case series or case reports." | 5.19 | A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. ( Chevrant-Breton, J; Chosidow, O; Cosnes, A; D'Incan, M; Desseaux, K; Droitcourt, C; Dupin, N; Dupuy, A; Joly, P; Juillard, C; Lacour, JP; Lebrun-Vignes, B; Misery, L; Porcher, R; Revuz, J; Rybojad, M; Sassolas, B; Tazi, A; Valeyre, D, 2014) |
| "To evaluate feasibility and efficacy of prolonged treatment with thalidomide for cutaneous sarcoidosis associated to pulmonary involvement in patients with resistance or contraindications to steroids." | 5.16 | Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. ( Antonelli, A; Barachini, P; Calabrese, R; Carpi, A; Cei, G; Cristofani, R; Fazzi, P; Manni, E; Piazza, S; Siciliano, G, 2012) |
| "The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum." | 5.12 | Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007) |
| "We sought to assess the efficacy and tolerance of thalidomide for cutaneous sarcoidosis." | 5.11 | Treatment of cutaneous sarcoidosis with thalidomide. ( Cordoliani, F; Dupuy, A; Lebbé, C; Morel, P; Nguyen, YT; Rybojad, M; Vignon-Pennamen, MD, 2004) |
| "Thalidomide was an effective form of treatment for chronic cutaneous sarcoidosis." | 5.10 | Thalidomide for chronic sarcoidosis. ( Baughman, RP; Judson, MA; Lower, EE; Moller, DR; Teirstein, AS, 2002) |
| "The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate." | 4.84 | Cutaneous sarcoidosis therapy updated. ( Badgwell, C; Rosen, T, 2007) |
| "We evaluated the antifibrotic effects of pomalidomide in preventive as well as therapeutic treatment regimes using bleomycin-induced dermal fibrosis as a model of early, inflammatory stages of fibrosis and the tight-skin mouse model as a model of later stages of fibrosis with endogenous activation of fibroblasts." | 3.78 | Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. ( Beyer, C; Cedzik, D; Dees, C; Distler, A; Distler, JH; Distler, O; Palumbo-Zerr, K; Schafer, PH; Schett, G; Shankar, SL; Tomcik, M; Weingärtner, S; Zerr, P, 2012) |
| " Thalidomide (N-phtalimidoglutarimide), initially used as a tranquilizer, has recently been used in the management of several inflammatory skin diseases." | 3.72 | Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide. ( Elsner, P; Kaatz, M; Sander, CS, 2004) |
| "Data from ten patients with sarcoidosis treated with thalidomide between January 1998 and March 1999 were collected from delivery authorizations and analyzed." | 3.71 | [Sarcoidosis: thalidomide treatment in ten patients]. ( Bressieux, JM; Cosnes, A; Estines, O; Revuz, J; Roujeau, JC; Wolkenstein, P, 2001) |
| "St Vincent's Hospital Melbourne cautiously prescribes thalidomide as a treatment for recalcitrant dermatoses." | 3.71 | Thalidomide experience of a major Australian teaching hospital. ( Baker, CS; Crouch, RB; Foley, PA; Ng, JC, 2002) |
| "Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM)." | 3.71 | The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. ( Grover, JK; Raina, V; Uppal, G, 2002) |
| "A patient with sarcoidosis was treated with thalidomide for disfiguring and painful steroid unresponsive sarcoidal granulomas of the skin." | 3.70 | Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. ( Koblenzer, PS; Lee, JB, 1998) |
| " Because administration of low doses of thalidomide has been successful in treating other inflammatory diseases, it was used in a patient with systemic sarcoidosis who was unresponsive to corticosteroids and in a patient with pulmonary sarcoidosis, in whom Kaposi's sarcoma developed after a course of corticosteroid therapy." | 3.69 | Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. ( Bonaccorsi, P; Calvieri, S; Carlesimo, M; Giustini, S; Rossi, A, 1995) |
| "Based on present publications we review indications of the therapy of dermatoses with thalidomide as well as possible mechanisms of action and side effects of this drug." | 3.66 | [Thalidomide in dermatology]. ( Hunziker, T; Krebs, A, 1983) |
| "Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and rituximab plus chemotherapy (with both regimens followed by rituximab maintenance therapy)." | 2.87 | Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. ( Ando, K; André, M; Bartlett, NL; Bouabdallah, K; Bouabdallah, R; Brice, P; Cartron, G; Casasnovas, RO; Daguindau, N; Feugier, P; Flinn, IW; Fowler, NH; Fruchart, C; Gomes da Silva, M; Haioun, C; Larouche, JF; Le Gouill, S; Libby, EN; Liu, D; López-Guillermo, A; Maisonneuve, H; Martin Garcia-Sancho, A; Morschhauser, F; Palomba, ML; Pica, GM; Ribrag, V; Salles, GA; Sehn, LH; Tilly, H; Tobinai, K; Wang, J; Xerri, L; Ysebaert, L; Zachée, P, 2018) |
| "Thalidomide's efficacy was suggested in an open study." | 2.68 | Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin. ( Bonnetblanc, JM; Claudy, A; Daniel, F; Dieng, MT; Guillaume, JC; Morel, P; Moulin, G; Poli, F; Souteyrand, P; Vaillant, L, 1995) |
| "Apremilast is an oral small-molecule phosphodiesterase 4 inhibitor with a multilevel immunomodulating mechanism of action." | 2.66 | On- and Off-Label Uses of Apremilast in Dermatology. ( Georgiou, S; Plachouri, KM, 2020) |
| "Thalidomide has immunomodulatory and anti-tumor necrosis factor-α effects as well as antiangiogenic properties, making it useful for a broad spectrum of inflammatory disorders." | 2.52 | Review of thalidomide use in the pediatric population. ( Antaya, RJ; Kim, C; Yang, CS, 2015) |
| "Sarcoidosis is a systemic granulomatous disease that affects numerous organs, commonly manifesting at the lungs and skin." | 2.52 | TNF-α: a treatment target or cause of sarcoidosis? ( Amber, KT; Bloom, R; Hertl, M; Mrowietz, U, 2015) |
| "New thalidomide analogues have been developed but lack clinical experience." | 2.50 | [Current therapeutic indications of thalidomide and lenalidomide]. ( Cosiglio, FJ; Ordi-Ros, J, 2014) |
| "Thalidomide is a beneficial agent for treating a variety of refractory dermatologic disorders including erythema nodosom leprosum, lupus erythematosus, prurigo nodularis, actinic prurigo, pyoderma gangrenosum and aphthous stomatitis." | 2.44 | Thalidomide and its dermatologic uses. ( Paghdal, KV; Schwartz, R, 2007) |
| "Thalidomide has several mechanisms of action: several immuno-modulatory properties, an anti-angiogenic action and a hypnosedative effect." | 2.43 | [The revival of thalidomide: an old drug with new indications]. ( Laffitte, E, 2006) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "Thalidomide has several mechanisms of action: a hypnosedative effect, several immuno-modulatory properties and an anti-angiogenic action." | 2.43 | [Thalidomide: new indications for an old drug]. ( Laffitte, E, 2005) |
| "Itch, also known as pruritus, is the major symptom in skin diseases with a variety of etiologies and pathophysiologies." | 2.42 | Itch associated with skin disease: advances in pathophysiology and emerging therapies. ( Fleischer, A; Yosipovitch, G, 2003) |
| "Thalidomide has several targets and mechanisms of action: a hypnosedative effect, several immunomodulatory properties with an effect on the production of TNF-alpha and the balance between the different lymphocyte subsets and an antiangiogenic action." | 2.42 | Thalidomide: an old drug with new clinical applications. ( Laffitte, E; Revuz, J, 2004) |
| "Thalidomide has been successful in the treatment of several dermatologic conditions unresponsive to other agents." | 2.41 | Thalidomide. ( Levine, N; Radomsky, CL, 2001) |
| " During the first 18 months of spontaneous postmarketing adverse event surveillance for Thalomid, 1210 spontaneous postmarketing adverse event reports were received for patients treated with prescription thalidomide for all therapeutic indications, including off-label use." | 2.41 | Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. ( Clark, TE; Edom, N; Larson, J; Lindsey, LJ, 2001) |
| "Thalidomide is an effective agent to treat over 25 seemingly unrelated dermatological conditions that have an inflammatory or autoimmune basis." | 2.41 | Thalidomide in dermatology. ( Cooper, AJ; Wines, MP; Wines, NY, 2002) |
| " Because TNF-alpha seems to be a central cytokine in UVR-induced apoptosis, the chronic use of TNF-alpha-altering drugs might increase the risk for skin cancers." | 2.41 | Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. ( Gaspari, AA; LaDuca, JR, 2001) |
| "Thalidomide has been used successfully in several other dermatologic disorders, including aphthous stomatitis, Behcet's syndrome, chronic cutaneous systemic lupus erythematosus, and graft-versus-host disease, the apparent shared characteristic of which is immune dysregulation." | 2.41 | Thalidomide: an antineoplastic agent. ( Amato, RJ, 2002) |
| "Thalidomide is a useful addition to the therapeutic armamentarium for treatment-resistant dermatoses as long as proper vigilance for adverse effects is maintained." | 2.39 | Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. ( Pak, G; Pomeranz, MK; Shupack, JL; Tseng, S; Washenik, K, 1996) |
| "Treatment with thalidomide stopped the progression of the disease in two cases." | 1.91 | Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report. ( Abdollahimajd, F; Diab, R; Kaddah, A; Rakhshan, A; Shahidi Dadras, M, 2023) |
| "Thalidomide therapy was introduced." | 1.39 | IgG4-related skin disease successfully treated by thalidomide: a report of 2 cases with emphasis on pathological aspects. ( Allanore, Y; Aucouturier, P; Chosidow, O; Elhai, M; Ingen-Housz-Oro, S; Ortonne, N, 2013) |
| "Thalidomide effectively treats some dermatologic conditions that are refractory to standard medications." | 1.35 | A case series of 48 patients treated with thalidomide. ( Doherty, SD; Hsu, S, 2008) |
| "Adult onset Langerhans cell histiocytosis is uncommon." | 1.31 | Langerhans' cell histiocytosis. ( Ehsani, A; Hosseini, M; Mortazavi, H; Namazi, MR, 2002) |
| "Thalidomide is a potentially useful drug for several dermatological disorders." | 1.31 | Thalidomide usage in Wales: the need to follow guidelines. ( Chave, TA; Finlay, AY; Knight, AG, 2001) |
| "Our data suggest that thalidomide treatment of sarcoidosis results in granuloma differentiation to a Th1-type cellular immune response usually associated with protective immunity to tuberculosis and tuberculoid leprosy." | 1.31 | Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. ( Kaplan, G; Kikuchi, T; Krueger, JG; Oliver, SJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (10.31) | 18.7374 |
| 1990's | 14 (14.43) | 18.2507 |
| 2000's | 44 (45.36) | 29.6817 |
| 2010's | 23 (23.71) | 24.3611 |
| 2020's | 6 (6.19) | 2.80 |
| Authors | Studies |
|---|---|
| Diab, R | 1 |
| Shahidi Dadras, M | 1 |
| Rakhshan, A | 1 |
| Kaddah, A | 1 |
| Abdollahimajd, F | 1 |
| Grimaldi, M | 1 |
| Perino, F | 1 |
| Moretta, G | 1 |
| Antonelli, F | 1 |
| Paradisi, A | 1 |
| Ricci, F | 1 |
| Abeni, D | 1 |
| Didona, B | 1 |
| Fania, L | 1 |
| Smith, L | 1 |
| Yesudian, PD | 1 |
| Murugusundaram, S | 1 |
| Krishnakumar, S | 1 |
| Yesudian, P | 1 |
| Arasu, A | 1 |
| Lee, S | 1 |
| Chian Yeoh, A | 1 |
| Ross, G | 1 |
| Plachouri, KM | 1 |
| Georgiou, S | 1 |
| Kalay Yildizhan, I | 1 |
| Sanli, H | 1 |
| Akay, BN | 1 |
| Erol, HM | 1 |
| Kuzu, I | 1 |
| Kırmızı, A | 1 |
| Cengiz Seval, G | 1 |
| Sakkas, LI | 1 |
| Mavropoulos, A | 1 |
| Bogdanos, DP | 1 |
| Roider, E | 1 |
| Signer, C | 1 |
| Fehrenbacher, B | 1 |
| Metzler, G | 1 |
| Schaller, M | 1 |
| Kamarachev, J | 1 |
| Kerl, K | 1 |
| Balabanov, S | 1 |
| Jochum, W | 1 |
| Hoetzenecker, W | 1 |
| Cozzio, A | 1 |
| French, LE | 1 |
| Dummer, R | 1 |
| Guenova, E | 1 |
| Morschhauser, F | 1 |
| Fowler, NH | 1 |
| Feugier, P | 1 |
| Bouabdallah, R | 1 |
| Tilly, H | 1 |
| Palomba, ML | 1 |
| Fruchart, C | 1 |
| Libby, EN | 1 |
| Casasnovas, RO | 1 |
| Flinn, IW | 1 |
| Haioun, C | 1 |
| Maisonneuve, H | 1 |
| Ysebaert, L | 1 |
| Bartlett, NL | 1 |
| Bouabdallah, K | 1 |
| Brice, P | 1 |
| Ribrag, V | 1 |
| Daguindau, N | 1 |
| Le Gouill, S | 1 |
| Pica, GM | 1 |
| Martin Garcia-Sancho, A | 1 |
| López-Guillermo, A | 1 |
| Larouche, JF | 1 |
| Ando, K | 1 |
| Gomes da Silva, M | 1 |
| André, M | 1 |
| Zachée, P | 1 |
| Sehn, LH | 1 |
| Tobinai, K | 1 |
| Cartron, G | 1 |
| Liu, D | 1 |
| Wang, J | 1 |
| Xerri, L | 1 |
| Salles, GA | 1 |
| Ingen-Housz-Oro, S | 2 |
| Ortonne, N | 2 |
| Elhai, M | 1 |
| Allanore, Y | 1 |
| Aucouturier, P | 1 |
| Chosidow, O | 3 |
| Li, X | 1 |
| Hong, Y | 1 |
| An, Q | 1 |
| Chen, J | 1 |
| Wei, H | 1 |
| Chen, HD | 1 |
| Gao, XH | 1 |
| Ordi-Ros, J | 1 |
| Cosiglio, FJ | 1 |
| Lehman, JS | 1 |
| Pittelkow, MR | 1 |
| Smyrk, TC | 1 |
| Fraser, K | 1 |
| Droitcourt, C | 1 |
| Rybojad, M | 2 |
| Porcher, R | 1 |
| Juillard, C | 1 |
| Cosnes, A | 2 |
| Joly, P | 1 |
| Lacour, JP | 1 |
| D'Incan, M | 1 |
| Dupin, N | 1 |
| Sassolas, B | 1 |
| Misery, L | 1 |
| Chevrant-Breton, J | 1 |
| Lebrun-Vignes, B | 1 |
| Desseaux, K | 1 |
| Valeyre, D | 1 |
| Revuz, J | 4 |
| Tazi, A | 1 |
| Dupuy, A | 2 |
| Taraborelli, M | 1 |
| Monari, P | 1 |
| Cavazzana, I | 1 |
| Gualdi, G | 1 |
| Calzavara-Pinton, P | 1 |
| Franceschini, F | 1 |
| Yang, CS | 1 |
| Kim, C | 1 |
| Antaya, RJ | 1 |
| Nadal, M | 1 |
| Kervarrec, T | 1 |
| Machet, MC | 2 |
| Petrella, T | 1 |
| Machet, L | 2 |
| Ong, N | 1 |
| McMeniman, E | 1 |
| Pillans, P | 1 |
| Soyer, HP | 1 |
| Amber, KT | 1 |
| Bloom, R | 1 |
| Mrowietz, U | 1 |
| Hertl, M | 1 |
| Azar, MM | 1 |
| Malinis, MF | 1 |
| Nahmias, Z | 1 |
| Nambudiri, VE | 1 |
| Vleugels, RA | 1 |
| Doherty, SD | 2 |
| Hsu, S | 3 |
| Chen, M | 1 |
| Passeron, T | 1 |
| Tóth, B | 1 |
| Katona, M | 1 |
| Hársing, J | 1 |
| Szepesi, A | 1 |
| Kárpáti, S | 1 |
| Baughman, RP | 2 |
| Judson, MA | 2 |
| Ingledue, R | 1 |
| Craft, NL | 1 |
| Lower, EE | 2 |
| Fazzi, P | 1 |
| Manni, E | 1 |
| Cristofani, R | 1 |
| Cei, G | 1 |
| Piazza, S | 1 |
| Calabrese, R | 1 |
| Antonelli, A | 1 |
| Siciliano, G | 1 |
| Barachini, P | 1 |
| Carpi, A | 1 |
| Weingärtner, S | 1 |
| Zerr, P | 1 |
| Tomcik, M | 1 |
| Palumbo-Zerr, K | 1 |
| Distler, A | 1 |
| Dees, C | 1 |
| Beyer, C | 1 |
| Shankar, SL | 1 |
| Cedzik, D | 1 |
| Schafer, PH | 1 |
| Distler, O | 1 |
| Schett, G | 1 |
| Distler, JH | 1 |
| Teirstein, AS | 1 |
| Moller, DR | 1 |
| Claudon, A | 1 |
| Dietemann, JL | 1 |
| Hamman De Compte, A | 1 |
| Hassler, P | 1 |
| Baidas, S | 1 |
| Tfayli, A | 1 |
| Bhargava, P | 1 |
| Grover, JK | 1 |
| Uppal, G | 1 |
| Raina, V | 1 |
| Wines, NY | 1 |
| Cooper, AJ | 1 |
| Wines, MP | 1 |
| Crouch, RB | 1 |
| Foley, PA | 1 |
| Ng, JC | 1 |
| Baker, CS | 1 |
| Kolde, G | 1 |
| Schulze, P | 1 |
| Sterry, W | 1 |
| Gaspari, A | 1 |
| Mortazavi, H | 1 |
| Ehsani, A | 1 |
| Namazi, MR | 1 |
| Hosseini, M | 1 |
| Waelput, F | 1 |
| Feremans, W | 1 |
| Heenen, M | 1 |
| Sternon, J | 1 |
| Gordon, JN | 1 |
| Goggin, PM | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Trechot, P | 1 |
| Yosipovitch, G | 1 |
| Fleischer, A | 1 |
| Laffitte, E | 4 |
| Nguyen, YT | 1 |
| Cordoliani, F | 1 |
| Vignon-Pennamen, MD | 1 |
| Lebbé, C | 1 |
| Morel, P | 2 |
| Sander, CS | 1 |
| Kaatz, M | 1 |
| Elsner, P | 1 |
| Franks, ME | 1 |
| Macpherson, GR | 1 |
| Figg, WD | 1 |
| Aranda, J | 1 |
| Hoang, MP | 1 |
| Cohen, JB | 1 |
| Peñas, PF | 1 |
| Fernández-Herrera, J | 1 |
| García-Diez, A | 1 |
| Faver, IR | 1 |
| Guerra, SG | 1 |
| Su, WP | 1 |
| el-Azhary, R | 1 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Tyring, SK | 1 |
| Saka, B | 1 |
| Erten, N | 1 |
| Oztürk, G | 1 |
| Yilmaz, C | 1 |
| Dogan, O | 1 |
| Buyukbabani, N | 1 |
| Besisik, SK | 1 |
| Nair, V | 1 |
| Sharma, A | 1 |
| Ghosh, I | 1 |
| Arora, S | 1 |
| Sahai, K | 1 |
| Dutta, V | 1 |
| Moravvej, H | 1 |
| Yousefi, M | 1 |
| Barikbin, B | 1 |
| Badgwell, C | 1 |
| Rosen, T | 1 |
| Paghdal, KV | 1 |
| Schwartz, R | 1 |
| Sharma, NL | 1 |
| Sharma, VC | 1 |
| Mahajan, VK | 1 |
| Shanker, V | 1 |
| Ranjan, N | 1 |
| Gupta, M | 1 |
| Grosshans, E | 1 |
| Illy, G | 1 |
| Barriere, H | 1 |
| Moulin, G | 2 |
| Bonnet, F | 1 |
| Barrut, D | 1 |
| Franc, MP | 1 |
| Hunziker, T | 1 |
| Krebs, A | 1 |
| dos Santos Júnior, MF | 1 |
| Lombardi, C | 1 |
| Belda, W | 1 |
| Dallafior, S | 1 |
| Pugin, P | 1 |
| Cerny, T | 1 |
| Betticher, D | 1 |
| Saurat, JH | 1 |
| Hauser, C | 1 |
| Guillaume, JC | 1 |
| Dieng, MT | 1 |
| Poli, F | 1 |
| Souteyrand, P | 1 |
| Bonnetblanc, JM | 1 |
| Claudy, A | 1 |
| Daniel, F | 1 |
| Vaillant, L | 2 |
| Carlesimo, M | 1 |
| Giustini, S | 1 |
| Rossi, A | 1 |
| Bonaccorsi, P | 1 |
| Calvieri, S | 1 |
| Meunier, L | 1 |
| Marck, Y | 1 |
| Ribeyre, C | 1 |
| Meynadier, J | 2 |
| Tseng, S | 1 |
| Pak, G | 1 |
| Washenik, K | 1 |
| Pomeranz, MK | 1 |
| Shupack, JL | 1 |
| Calderon, P | 1 |
| Anzilotti, M | 1 |
| Phelps, R | 1 |
| Rousseau, L | 1 |
| Beylot-Barry, M | 1 |
| Doutre, MS | 1 |
| Beylot, C | 1 |
| Grasland, A | 1 |
| Pouchot, J | 1 |
| Chaumaizière, D | 1 |
| Aitken, G | 1 |
| Vinceneux, P | 1 |
| Lee, JB | 1 |
| Koblenzer, PS | 1 |
| Stirling, DI | 1 |
| Pizarro, A | 1 |
| García-Tobaruela, A | 1 |
| Herranz, P | 1 |
| Pinilla, J | 1 |
| Myers, SA | 1 |
| Radomsky, CL | 1 |
| Levine, N | 1 |
| Clark, TE | 1 |
| Edom, N | 1 |
| Larson, J | 1 |
| Lindsey, LJ | 1 |
| Chave, TA | 1 |
| Finlay, AY | 1 |
| Knight, AG | 1 |
| McCauliffe, DP | 1 |
| Moraes, M | 1 |
| Russo, G | 1 |
| Estines, O | 1 |
| Wolkenstein, P | 1 |
| Bressieux, JM | 1 |
| Roujeau, JC | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| LaDuca, JR | 1 |
| Gaspari, AA | 1 |
| Hoch, O | 1 |
| Müller, S | 1 |
| Büttner, G | 1 |
| Mensing, H | 1 |
| Amato, RJ | 1 |
| Oliver, SJ | 1 |
| Kikuchi, T | 1 |
| Krueger, JG | 1 |
| Kaplan, G | 1 |
| Ochsendorf, F | 1 |
| Kaufmann, R | 1 |
| Bahmer, FA | 1 |
| Bensaid, P | 1 |
| Scotto, B | 1 |
| Lorette, G | 1 |
| Peyron, JL | 1 |
| Naafs, B | 1 |
| Faber, WR | 1 |
| Koch, HP | 1 |
| Keplinger, ML | 1 |
| Fancher, OE | 1 |
| Lyman, FL | 1 |
| Calandra, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647] | Phase 2 | 4 participants (Actual) | Interventional | 2020-11-23 | Completed | ||
| "A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The RELEVANCE Trial (Ritu[NCT01650701] | Phase 3 | 1,030 participants (Actual) | Interventional | 2012-02-29 | Active, not recruiting | ||
| A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma[NCT01938001] | Phase 3 | 358 participants (Actual) | Interventional | 2013-11-21 | Completed | ||
| A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma[NCT01476787] | Phase 3 | 255 participants (Actual) | Interventional | 2011-12-29 | Active, not recruiting | ||
| Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis[NCT00305552] | Phase 3 | 40 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis[NCT00794274] | Phase 2/Phase 3 | 15 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Evaluation of Provase in the Post Burn Rehabilitation Population for Itch Control and Moisturization Properties[NCT00782054] | Phase 4 | 23 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
DCCR was defined as the percentage of participants with a best response of complete response (CR) that lasted no less than one year (≥ 48 weeks) during the study prior to administration of new anti-lymphoma therapy. A CR is defined as a complete disappearance of any disease-related symptoms and normalization of biochemical abnormalities. (NCT01938001)
Timeframe: From first dose of investigational product (IP) to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomiade arm and 11.04 months in the rituximab/placebo arm
| Intervention | Percentage of Participants (Number) |
|---|---|
| Rituximab + Lenalidomide (R^2) | 25.3 |
| Rituximab + Placebo | 11.1 |
Event-free survival (EFS) was defined as the time from date of randomization to date of first documented progression, relapse, institution of new anti-lymphoma treatment (chemotherapy, radiotherapy or immunotherapy) or death from any cause. Responding participants and those who were lost to follow up were censored at their last tumor assessment date. (NCT01938001)
Timeframe: From date of randomization to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
| Intervention | months (Median) |
|---|---|
| Rituximab + Lenalidomide (R^2) | 27.6 |
| Rituximab + Placebo | 13.9 |
Progression-free survival (PFS) was defined as the time from date of randomization into the study to the first observation of documented disease progression or death due to any cause, whichever occurred first. PFS was based on the data from the IRC review using the modified 2007 International Working Group Response Criteria (IWGRC) using FDA censoring rules. (NCT01938001)
Timeframe: From randomization of study drug up to disease progression or death, which occurred first; up to the data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
| Intervention | months (Median) |
|---|---|
| Rituximab + Lenalidomide (R^2) | 39.4 |
| Rituximab + Placebo | 14.1 |
Time to next anti-lymphoma treatment (TTNLT) was defined as the time from date of randomization to date of first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy or immunotherapy). The time to the next anti-lymphoma treatment was of special interest to the study. (NCT01938001)
Timeframe: From date of randomization to date of first documented administration of a new anti-lymphoma treatment (Average of 55.71 months and a maximum up to 95.2 months)
| Intervention | Months (Median) |
|---|---|
| Rituximab + Lenalidomide (R^2) | 73.1 |
| Rituximab + Placebo | 31.8 |
DOCR was defined as the time from initial CR until documented PD or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free. (NCT01938001)
Timeframe: From randomization up to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
| Intervention | months (Median) |
|---|---|
| Rituximab + Lenalidomide (R^2) | NA |
| Rituximab + Placebo | NA |
Duration of response (DOR) was defined as the time from initial response (at least PR) until documented progressive disease (PD) or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free. (NCT01938001)
Timeframe: From randomization up to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
| Intervention | months (Median) |
|---|---|
| Rituximab + Lenalidomide (R^2) | 36.6 |
| Rituximab + Placebo | 21.7 |
Overall survival was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01938001)
Timeframe: From date of randomization to death due to any cause (Average of 55.71 months and a maximum up to 95.2 months)
| Intervention | Months (Median) |
|---|---|
| Rituximab + Lenalidomide (R^2) | NA |
| Rituximab + Placebo | NA |
Percentage of participants with a best response of at CR during the study without administration of new anti-lymphoma therapy. A CR = Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities. (NCT01938001)
Timeframe: From date of first dose up to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomide arm and 11.04 months in the rituximab/placebo arm
| Intervention | Percentage of Participants (Number) |
|---|---|
| Rituximab + Lenalidomide (R^2) | 33.7 |
| Rituximab + Placebo | 18.3 |
Percentage of participants with an objective response is defined as having a response of at least a PR during the study without administration of new anti-lymphoma therapy. A complete response = a complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities; a partial response (PR) = 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. (NCT01938001)
Timeframe: From date of first dose to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomide arm and 11.04 months in the rituximab/placebo arm
| Intervention | Percentage of Participants (Number) |
|---|---|
| Rituximab + Lenalidomide (R^2) | 77.5 |
| Rituximab + Placebo | 53.3 |
TEAEs include AEs that started or worsened between the date of the first dose and 28 days after the date of the last dose. A serious adverse event (SAE) is any: • Death; • Life-threatening event; • Any inpatient hospitalization or prolongation of existing hospitalization; • Persistent or significant disability or incapacity; • Congenital anomaly or birth defect; • Any other important medical event. The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death (NCT01938001)
Timeframe: From first dose to 28 days post last dose (Average of 55.71 months and a maximum up to 95.2 months)
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Any TEAE Related to Lenalidomide/Placebo (LEN/PBO) | Any TEAE Related to Rituximab (RIT) | Any Serious TEAE | Any Serious TEAE Related to LEN/PBO | Any Serious TEAE Related to RIT | Any CTCAE Grade (GR) 3/4 TEAE | Any CTCAE GR 3/4 TEAE Related to LEN/PBO | Any CTCAE GR 3/4 TEAE Related to RIT | Any GR 5 TEAE | Any TEAE Leading to Dose Reduction LEN/PBO | Any TEAE Leading to Dose Interruption LEN/PBO | Any TEAE Leading to Dose Interruption RIT | Any TEAE Leading to Discontinuation of LEN/PBO | Any TEAE Leading to Discontinuation of RIT | |
| Rituximab + Lenalidomide (R^2) | 174 | 159 | 134 | 45 | 23 | 13 | 121 | 101 | 57 | 2 | 46 | 113 | 59 | 15 | 6 |
| Rituximab + Placebo | 173 | 118 | 105 | 25 | 8 | 4 | 58 | 38 | 20 | 2 | 6 | 47 | 38 | 9 | 2 |
37 reviews available for thalidomide and Skin Diseases
| Article | Year |
|---|---|
On- and Off-Label Uses of Apremilast in Dermatology.
Topics: Humans; Off-Label Use; Phosphodiesterase 4 Inhibitors; Psoriasis; Skin Diseases; Thalidomide | 2020 |
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Topics: Aminopyridines; Autoimmune Diseases; Benzamides; Boron Compounds; Cyclopropanes; Eye Diseases; Human | 2017 |
[Current therapeutic indications of thalidomide and lenalidomide].
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; End | 2014 |
Review of thalidomide use in the pediatric population.
Topics: Abnormalities, Drug-Induced; Adolescent; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Au | 2015 |
TNF-α: a treatment target or cause of sarcoidosis?
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Etanercept; Granuloma; Hum | 2015 |
Innovative uses of thalidomide.
Topics: Contraindications; Female; Humans; Leprostatic Agents; Male; Off-Label Use; Skin Diseases; Thalidomi | 2010 |
[What's new in dermatological research?].
Topics: Biomedical Research; Dermatitis, Atopic; Dermatology; Herpesviridae Infections; HIV Infections; Huma | 2010 |
Thalidomide: an old drug with new clinical applications.
Topics: Autoimmune Diseases; HIV Infections; Humans; Immunosuppressive Agents; Neoplasms; Skin Diseases; Tha | 2002 |
Thalidomide in dermatology.
Topics: Dermatologic Agents; Humans; Neoplasms; Skin Diseases; Thalidomide | 2002 |
Thalidomide neurotoxicity in dermatological patients: the next "STEP".
Topics: Dermatologic Agents; Humans; Neurotoxins; Skin Diseases; Thalidomide | 2002 |
[Renaissance of thalidomide].
Topics: Humans; Immunosuppressive Agents; Multiple Myeloma; Skin Diseases; Thalidomide | 2002 |
Thalidomide and its derivatives: emerging from the wilderness.
Topics: Adjuvants, Immunologic; Cachexia; Crohn Disease; Graft vs Host Disease; Hematologic Neoplasms; Human | 2003 |
Itch associated with skin disease: advances in pathophysiology and emerging therapies.
Topics: Adjuvants, Immunologic; Arachidonic Acid; Capsaicin; Electric Stimulation; Histamine H1 Antagonists; | 2003 |
Thalidomide: an old drug with new clinical applications.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Hypnotics and Sed | 2004 |
Thalidomide.
Topics: Clinical Trials as Topic; Gastrointestinal Diseases; HIV Infections; Humans; Neoplasms; Rheumatic Di | 2004 |
Dermatologic treatment of cutaneous graft versus host disease.
Topics: Clinical Trials as Topic; Etretinate; Graft vs Host Disease; Humans; Immunosuppressive Agents; PUVA | 2004 |
Thalidomide for dermatology: a review of clinical uses and adverse effects.
Topics: Animals; Anti-Inflammatory Agents; Dermatologic Agents; Humans; Immunosuppressive Agents; Skin Disea | 2005 |
[Thalidomide: new indications for an old drug].
Topics: Humans; Skin Diseases; Thalidomide | 2005 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
Cutaneous sarcoidosis therapy updated.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Allopurinol; Animals; Anti-Inflammatory Agents | 2007 |
[The revival of thalidomide: an old drug with new indications].
Topics: Angiogenesis Inhibitors; Drug Eruptions; Humans; Leprostatic Agents; Peripheral Nervous System Disea | 2006 |
Thalidomide and its dermatologic uses.
Topics: Dermatologic Agents; Humans; Skin Diseases; Thalidomide | 2007 |
Thalidomide therapy for inflammatory dermatoses.
Topics: Abnormalities, Drug-Induced; Adult; Animals; Chemical Phenomena; Chemistry; Female; Humans; Immunity | 1984 |
Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.
Topics: Humans; Skin Diseases; Thalidomide | 1996 |
Thalidomide in dermatology. New indications for an old drug.
Topics: Abnormalities, Drug-Induced; Erythema Nodosum; History, 20th Century; Humans; Immunosuppressive Agen | 1997 |
Thalidomide and its impact in dermatology.
Topics: Dermatologic Agents; Humans; Skin Diseases; Thalidomide | 1998 |
Update on new immunomodulatory agents.
Topics: Adjuvants, Immunologic; Humans; Mycophenolic Acid; Skin Diseases; Tacrolimus; Thalidomide | 2000 |
Thalidomide.
Topics: Dermatologic Agents; Humans; Immunosuppressive Agents; Practice Guidelines as Topic; Skin Diseases; | 2001 |
Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Drug Labeling; Erythema Nodosum; Female; Hallucinations; H | 2001 |
Cutaneous lupus erythematosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Biopsy; Clofazimine; Dermatologic Agents; Di | 2001 |
Thalidomide and its dermatologic uses.
Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D | 2001 |
[New indications for thalidomide?].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiogenesis Inhibitors; Animals; Anti-HIV Agents; A | 2001 |
Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
Topics: Animals; Antibodies, Monoclonal; Dermatologic Agents; Etanercept; Humans; Immunoglobulin G; Inflamma | 2001 |
Thalidomide: an antineoplastic agent.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; HIV Infections; H | 2002 |
[Langerhans-cell histiocytosis in the adult: regressive parotid involvement following thalidomide therapy].
Topics: Adult; Female; Histiocytosis, Langerhans-Cell; Humans; Intertrigo; Parotid Diseases; Pregnancy; Preg | 1992 |
The pharmacological basis for the treatment of photodermatoses.
Topics: Antigens; Antimalarials; beta Carotene; Carotenoids; DNA; Female; Humans; Immunosuppression Therapy; | 1986 |
Thalidomide and congeners as anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Gastrointestinal Diseases; Humans; Immunos | 1985 |
9 trials available for thalidomide and Skin Diseases
| Article | Year |
|---|---|
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2018 |
A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis.
Topics: Adult; Aged; Double-Blind Method; Female; France; Humans; Immunosuppressive Agents; Male; Middle Age | 2014 |
Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.
Topics: Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Sarcoidosis; Severity of Illness Index; Skin D | 2012 |
Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids.
Topics: Adult; Aged; Contraindications; Dose-Response Relationship, Drug; Drug Resistance; Feasibility Studi | 2012 |
Thalidomide for chronic sarcoidosis.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; | 2002 |
Treatment of cutaneous sarcoidosis with thalidomide.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Male; Middle Aged | 2004 |
Thalidomide: an experience in therapeutic outcome and adverse reactions.
Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen | 2007 |
[Treatment of Jessner-Kanof disease with thalidomide].
Topics: Adult; Clinical Trials as Topic; Diagnosis, Differential; Female; Humans; Lupus Erythematosus, Disco | 1983 |
Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Prospective Studi | 1995 |
51 other studies available for thalidomide and Skin Diseases
| Article | Year |
|---|---|
Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report.
Topics: Adult; Female; Histiocytosis; Humans; Skin Diseases; Skin Neoplasms; Thalidomide | 2023 |
Cutaneous Rosai-Dorfman disease after Covid 19 vaccination treated with thalidomide.
Topics: COVID-19; COVID-19 Vaccines; Histiocytosis, Sinus; Humans; Skin Diseases; Thalidomide; Vaccination | 2022 |
IgG4-related skin disease responsive to thalidomide.
Topics: Humans; Immunoglobulin G; Immunosuppressive Agents; Skin; Skin Diseases; Thalidomide | 2023 |
Drug survival of thalidomide for dermatological conditions: A single-centre review.
Topics: Dermatologic Agents; Humans; Prurigo; Skin Diseases; Stomatitis, Aphthous; Thalidomide | 2021 |
Rosai-Dorfman disease presenting with nasal, nodal and multiple cutaneous involvements responding to a combination of systemic steroid and low-dose thalidomide therapy.
Topics: Histiocytosis, Sinus; Humans; Nose; Skin Diseases; Steroids; Thalidomide | 2021 |
Individualized treatment approaches for Langerhans cell histiocytosis.
Topics: Adrenal Cortex Hormones; Adult; Aged, 80 and over; Azetidines; Bone Diseases; Dermatologic Agents; F | 2018 |
IgG4-related skin disease successfully treated by thalidomide: a report of 2 cases with emphasis on pathological aspects.
Topics: Adult; Forkhead Transcription Factors; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Mid | 2013 |
Successful treatment of Rosai-Dorfman disease with low-dose oral thalidomide.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Follow-Up Studies; Histiocytosis, Sin | 2013 |
IgG4-related skin disease.
Topics: Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Skin Diseases; Thalidomide | 2013 |
IgG4-related skin disease--reply.
Topics: Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Skin Diseases; Thalidomide | 2013 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, | 2014 |
Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide.
Topics: Aged; Cryoglobulinemia; Humans; Immunosuppressive Agents; Male; Skin Diseases; Skin Ulcer; Thalidomi | 2015 |
Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide.
Topics: Acitretin; Administration, Cutaneous; Aged; Anti-Inflammatory Agents; Breast Diseases; Clobetasol; D | 2015 |
A clinical audit of high-cost and off-label drug use in dermatology.
Topics: Adalimumab; Adult; Aged; Aged, 80 and over; Cyclosporine; Dermatologic Agents; Dermatology; Female; | 2017 |
Disseminated Histoplasmosis with Skin Lesions and Osteomyelitis in a Patient from the Philippines.
Topics: Administration, Intravenous; Administration, Oral; Aged; Amphotericin B; Cefepime; Cephalosporins; D | 2016 |
Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions.
Topics: Adult; Aged; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Retreatment; Skin | 2016 |
A case series of 48 patients treated with thalidomide.
Topics: Adult; Female; Humans; Immunosuppressive Agents; Leprostatic Agents; Male; Middle Aged; Peripheral N | 2008 |
Indeterminate cell histiocytosis in a pediatric patient: successful treatment with thalidomide.
Topics: Adolescent; Histiocytosis; Humans; Immunosuppressive Agents; Male; Skin Diseases; Thalidomide; Treat | 2012 |
Pomalidomide is effective for prevention and treatment of experimental skin fibrosis.
Topics: Animals; Disease Models, Animal; Fibrosis; Hydroxyproline; Immunosuppressive Agents; Mice; Mice, Inb | 2012 |
[Interest in thalidomide in cutaneo-mucous and hypothalamo-hypophyseal involvement of Langerhans cell histiocytosis].
Topics: Adult; Female; Genital Diseases, Female; Histiocytosis, Langerhans-Cell; Humans; Hypothalamic Diseas | 2002 |
The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma.
Topics: Adult; Aged; Constipation; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Immunosuppress | 2002 |
Thalidomide experience of a major Australian teaching hospital.
Topics: Adolescent; Adult; Aged; Behcet Syndrome; Dermatologic Agents; Female; Humans; Lupus Erythematosus, | 2002 |
Mixed response to thalidomide therapy in adults: two cases of multisystem Langerhans' cell histiocytosis.
Topics: Administration, Oral; Adult; Anus Diseases; Dose-Response Relationship, Drug; Drug Administration Sc | 2002 |
Langerhans' cell histiocytosis.
Topics: Adult; Histiocytosis, Langerhans-Cell; Humans; Male; Skin Diseases; Thalidomide | 2002 |
[Thalidomide and thrombosis].
Topics: Adult; Aged; Clinical Trials as Topic; Dermatologic Agents; Drug Interactions; Drug Therapy, Combina | 2003 |
Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide.
Topics: Administration, Oral; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration S | 2004 |
Shiny red-brown papules in a 21-year-old man. Histoid leprosy.
Topics: Adult; Clofazimine; Dapsone; Diagnosis, Differential; Drug Therapy, Combination; Face; Humans; Lepro | 2004 |
Kappa light chain myeloma with initial cutaneous involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Drug Resistance, Neoplas | 2006 |
Extensive chronic graft-versus-host disease of skin successfully treated with thalidomide.
Topics: Adult; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chron | 2005 |
An unusual case of adult disseminated cutaneous Langerhans cell histiocytosis.
Topics: Adult; Antigens, CD1; Biomarkers; Combined Modality Therapy; Cyclosporine; Histiocytosis, Langerhans | 2006 |
[Thalidomide].
Topics: Humans; Skin Diseases; Thalidomide | 2007 |
[Cutaneous sarcoidosis. Treatment with thalidomide].
Topics: Humans; Sarcoidosis; Skin Diseases; Thalidomide | 1983 |
[Thalidomide in dermatology].
Topics: Animals; Female; Guinea Pigs; Humans; Immunity; Leprosy; Lupus Erythematosus, Discoid; Male; Mice; N | 1983 |
[Thalidomide: a review of the literature].
Topics: Animals; Chemical Phenomena; Chemistry; Erythema Nodosum; Humans; Leprosy; Rats; Skin Diseases; Tera | 1981 |
[Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide].
Topics: Aged; Cladribine; Drug Therapy, Combination; Female; Histiocytosis, Langerhans-Cell; Humans; Immunos | 1995 |
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
Topics: Aged; Female; Humans; Middle Aged; Sarcoidosis; Sarcoidosis, Pulmonary; Sarcoma, Kaposi; Skin Diseas | 1995 |
Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment.
Topics: Aged; Histiocytosis, Langerhans-Cell; Humans; Male; Skin Diseases; Thalidomide | 1995 |
Cutaneous sarcoidosis successfully treated with low doses of thalidomide.
Topics: Adult; Cicatrix; Female; Fibrosis; Humans; Immunosuppressive Agents; Sarcoidosis; Skin Diseases; Tha | 1998 |
[Effectiveness of thalidomide treatment during cutaneous sarcoidosis].
Topics: Dermatologic Agents; Female; Humans; Middle Aged; Sarcoidosis; Skin Diseases; Thalidomide; Treatment | 1998 |
Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report.
Topics: Dermatologic Agents; Drug Administration Schedule; Facial Dermatoses; Female; Fingers; Glucocorticoi | 1998 |
Thalidomide as an inhibitor of tumor necrosis factor-alpha production: a word of caution.
Topics: Humans; Skin Diseases; Thalidomide; Tumor Necrosis Factor-alpha | 1999 |
Thalidomide: new preparation. For well-defined indications.
Topics: Behcet Syndrome; Clinical Trials as Topic; Erythema Nodosum; France; Graft vs Host Disease; Humans; | 1998 |
Thalidomide usage in Wales: the need to follow guidelines.
Topics: Dermatologic Agents; Dermatology; Drug Utilization; Guideline Adherence; Humans; Informed Consent; N | 2001 |
[Sarcoidosis: thalidomide treatment in ten patients].
Topics: Chronic Disease; Dermatologic Agents; Drug Administration Schedule; Humans; Immunosuppressive Agents | 2001 |
[Thalidomide in the treatment of cutaneous and systemic sarcoidosis].
Topics: Adult; Dermatologic Agents; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Male; Middle | 2001 |
Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement.
Topics: Adult; Antigens, CD; Dendritic Cells; Dermatologic Agents; Female; Flow Cytometry; HLA-DR Antigens; | 2002 |
[Comment on O. Hoch et al.: "Thalidomide in treatment of cutaneous and systemic sarcoidosis"].
Topics: Humans; Sarcoidosis; Skin Diseases; Thalidomide; Treatment Outcome | 2002 |
[Therapy of lymphocytic infiltration].
Topics: Azathioprine; Clofazimine; Cyclosporine; Dapsone; Humans; Levamisole; Lymphocytosis; Skin; Skin Dise | 1992 |
Thalidomide in dermatology and leprosy.
Topics: Female; Humans; Leprosy; Male; Pregnancy; Skin Diseases; Thalidomide | 1985 |
Thalidomide therapy. An open trial.
Topics: Adult; Aged; Central Nervous System Diseases; Erythema Multiforme; Female; Humans; Lichen Planus; Lu | 1985 |
Toxicologic studies of four fluorescent whitening agents.
Topics: Abnormalities, Drug-Induced; Animals; Dogs; Dose-Response Relationship, Drug; Drug Hypersensitivity; | 1974 |